Terms: = Lung cancer AND CDKN2C, P42773, 1031, ENSG00000123080, INK4C, p18, p18-INK4C AND Treatment
24 results:
1. MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma.
Liang J; Bi G; Huang Y; Zhao G; Sui Q; Zhang H; Bian Y; Yin J; Wang Q; Chen Z; Zhan C
Drug Resist Updat; 2024 Mar; 73():101057. PubMed ID: 38266355
[TBL] [Abstract] [Full Text] [Related]
2. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
Desai A; Rakshit S; Bansal R; Ashara Y; Potter A; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Schwecke A; Moffett N; Hocum C; Leventakos K; Adjei A; Marks R; Molina J; Mansfield AS; Chen ZM; Dimou A
Cancer Treat Res Commun; 2023; 36():100743. PubMed ID: 37531736
[TBL] [Abstract] [Full Text] [Related]
3. Patient-Derived In Vitro and In Vivo Models of cancer.
Claridge SE; Cavallo JA; Hopkins BD
Adv Exp Med Biol; 2022; 1361():215-233. PubMed ID: 35230691
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of a small molecule inhibitor of the transcriptional cofactor PC4 in prevention and treatment of non-small cell lung cancer.
Zhang Y; Pavlov A; Malik S; Chen H; Kim N; Li Z; Zhang X; DePamphilis ML; Roeder RG; Ge H
PLoS One; 2020; 15(3):e0230670. PubMed ID: 32231397
[TBL] [Abstract] [Full Text] [Related]
5. Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data.
Colinet B; Van Meerbeeck JP; Cuppens T; Vansteenkiste JF
Acta Clin Belg; 2021 Jun; 76(3):224-231. PubMed ID: 31935159
[No Abstract] [Full Text] [Related]
6. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell lung cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract] [Full Text] [Related]
7. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717
[TBL] [Abstract] [Full Text] [Related]
8. Predicting delays in lung cancer diagnosis and staging.
Leiro-Fernández V; Mouronte-Roibás C; García-Rodríguez E; Botana-Rial M; Ramos-Hernández C; Torres-Durán M; Ruano-Raviña A; Fernández-Villar A;
Thorac Cancer; 2019 Feb; 10(2):296-303. PubMed ID: 30605236
[TBL] [Abstract] [Full Text] [Related]
9. Complementary Medicine, Refusal of Conventional cancer Therapy, and Survival Among Patients With Curable cancers.
Johnson SB; Park HS; Gross CP; Yu JB
JAMA Oncol; 2018 Oct; 4(10):1375-1381. PubMed ID: 30027204
[TBL] [Abstract] [Full Text] [Related]
10. Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study.
Jiang Y; Zhao J; Zhang Y; Li K; Li T; Chen X; Zhao S; Zhao S; Liu K; Dong Z
J Transl Med; 2018 May; 16(1):138. PubMed ID: 29788985
[TBL] [Abstract] [Full Text] [Related]
11. An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
Shafrin J; Skornicki M; Brauer M; Villeneuve J; Lees M; Hertel N; Penrod JR; Jansen J
Health Policy; 2018 Jun; 122(6):607-613. PubMed ID: 29731176
[TBL] [Abstract] [Full Text] [Related]
12. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer.
Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
Int J Clin Oncol; 2017 Aug; 22(4):690-697. PubMed ID: 28382561
[TBL] [Abstract] [Full Text] [Related]
13. Expression level is a key determinant of E2F1-mediated cell fate.
Shats I; Deng M; Davidovich A; Zhang C; Kwon JS; Manandhar D; Gordân R; Yao G; You L
Cell Death Differ; 2017 Apr; 24(4):626-637. PubMed ID: 28211871
[TBL] [Abstract] [Full Text] [Related]
14. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders.
Sarkozy C; Kaltenbach S; Faurie P; Canioni D; Berger F; Traverse-Glehen A; Ghesquieres H; Salles G; Bachy E; Alyanakian MA; Hermine O; Neven B; Macintyre E; Romana S; Molina TJ; Suarez F; Asnafi V; Bruneau J
Genes Chromosomes Cancer; 2017 Mar; 56(3):221-230. PubMed ID: 27750397
[TBL] [Abstract] [Full Text] [Related]
15. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
[TBL] [Abstract] [Full Text] [Related]
16. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
[TBL] [Abstract] [Full Text] [Related]
17. Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.
Mateen S; Tyagi A; Agarwal C; Singh RP; Agarwal R
Mol Carcinog; 2010 Mar; 49(3):247-58. PubMed ID: 19908243
[TBL] [Abstract] [Full Text] [Related]
18. [treatment and prognosis of low-grade malignant endometrial stromal sarcoma].
Ma SK; Zhang HT; Wu LY; Liu LY; Li B
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):74-8. PubMed ID: 17575701
[TBL] [Abstract] [Full Text] [Related]
19. Epstein-Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy.
Stevens SJ; Zwaan CM; Verkuijlen SA; Middeldorp JM
Head Neck; 2006 Nov; 28(11):1040-5. PubMed ID: 16933315
[TBL] [Abstract] [Full Text] [Related]
20. Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study.
Syrigos KN; Dannos I; Dionellis G; Bofos I; Alamara C; Dimakou E; Stratakos G; Papiris S
Anticancer Res; 2005; 25(5):3489-93. PubMed ID: 16101167
[TBL] [Abstract] [Full Text] [Related]
[Next]
